Public Policy Newsletter
April 28, 2017
Takeaway and Photos from the Biocom 2017 Oncology Fly-In!
On April 5-7, Biocom brought a small group of California companies to Washington DC as part of our Oncology Advocacy Fly-In to learn about our regulatory and legislative environments. The event also allowed executives to educate DC officials about new advances in cancer research, our California life science community, and the challenges they face to develop these life-saving therapies and products. Click here to view the press release.
Participants had the opportunity to meet with officials at the Food and Drug Administration (FDA), including the Director of the Center for Devices and Radiologic Health (CDRH), the National Cancer Institute’s (NCI) SBIR/STTR office, the Centers for Medicare and Medicaid Services (CMS), the Energy & Commerce Committee, and the offices of Representatives Mimi Walters (R-45), Scott Peters (D-52), and Susan Davis (D-53).
"We are thankful to Biocom for opening doors for us to learn directly from senior staff at FDA, CMS, NCI and Congress about opportunities available to help support companies with their regulatory, reimbursement, and financing needs," added Ryan Witt, vice president, Immix Biopharma. "The symbiosis of companies of all sizes uniting under Biocom's umbrella to have a voice greater than our own is why we are thrilled to be part of this community that Biocom is supporting in the region."
Participants discussed a broad range of issues including FDA’s Oncology Center of Excellence, companion diagnostics for rare diseases, the reauthorization of FDA user fees, funding for the National Institutes of Health (NIH), the Cancer Moonshot Initiative, SBIR/STTR grants, the coverage determination process, the parallel review program, and tax reform, among many others.
First Ever Earth Day Reception Showcases Member Sustainability Advances
Biocom's Public Policy team proudly works with member companies to achieve their sustainability goals. Read more about these efforts and last week's event here.
Save the Date for our First Bay Area Facilities/EH&S Committee Meeting
Join us May 23rd! For more information and to register, clickhere.
Biocom Supports Port of SF Mission Bay Ferry Landing
Biocom is communicating with local government to encourage the San Francisco Transportation Authority to move forward with this new facility. Click here to learn more.
Biocom Holds Successful Roundtable with San Diego City Councilmembers
Councilmembers Bry and Ward discussed issues important to the life science industry in San Diego. To read more, click here.
Uncertainty Over ACA Repeal and Spending Bill Votes
For a detailed summary of both of these issues, click here.
FDA Commissioner Nomination Approved by Senate Committee
The announcement was welcomed by the industry and applauded by Biocom. For a brief background on Gottlieb and his confirmation hearing, click here.
Senate and House Health Committees Release FDA User Fees Reauthorization Draft
Learn more about the draft and its corresponding amendments here.
FDA Announces Workshop on How to Successfully Engage with FDA's Drug Center
For more information and to register, click here.
Member of Biocom Board Testifies Against SB 17, Bill Banning Co-pay Coupons Advances
Click here for a a summary on these bills and their impact on the industry.
Proposed California Tax on Opioids Passes First Committee
Read more on the bill and Biocom's opposition here.
Legislation to Create Single Payer Health in California Passes First Committee
For a detailed summary on the hearing, click here.